✦ LIBER ✦

PND23 Economic Evaluation of Natalizumab Versus Fingolimod for the Treatment of Relapsing-Remitting Multiple Sclerosis in Sweden

✍ Scribed by S.T. Alexopoulos; B. Deniz; A.R. Walker; R. Arnold; D. Bates

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PND25 ECONOMIC EVALUATION OF NATALIZUMAB

✍ C Brennig; E Walter; V Schöllbauer 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

Cost-effectiveness of natalizumab versus

✍ O’Day, Ken; Meyer, Kellie; Miller, Ross M.; Agarwal, Sonalee; Franklin, Meg 📂 Article 📅 2011 🏛 Informa plc 🌐 English ⚖ 373 KB

PND33 Cost Minimization Analysis of Fing

✍ B. Verheggen; M. Treur; M. Groot 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

PND30 Cost Analysis of Glatiramer Acetat

✍ Sánchez-de la Rosa, R.; Sabater, E.; Casado, M.A. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

PND32 Economic Evaluation of Natalizumab

✍ Reyes, A.; Sánchez-Mejorada, G.; Trejo, W. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

Cost minimisation analysis of fingolimod

✍ Crespo, C.; Izquierdo, G.; García-Ruiz, A.; Granell, M.; Brosa, M. 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 480 KB